Details for Patent: 12,303,493
✉ Email this page to a colleague
Which drugs does patent 12,303,493 protect, and when does it expire?
Patent 12,303,493 protects ERLEADA and is included in one NDA.
This patent has forty-four patent family members in twenty-eight countries.
Summary for Patent: 12,303,493
| Title: | Anticancer compositions |
| Abstract: | The present invention concerns pharmaceutical formulations of ARN-509, which can be administered to a mammal, in particular a human, suffering from an androgen receptor (AR)-related disease or condition, in particular cancer, more in particular prostate cancer, including but not limited to castration-resistant prostate cancer, metastatic castration resistant prostate cancer, chemotherapy-naive metastatic castration resistant prostate cancer, biochemically relapsed hormone sensitive prostate cancer, or high-risk, non-metastatic castration-resistant prostate cancer. In one aspect, these formulations comprise a solid dispersion of ARN-509 and HPMCAS. In one aspect, the solid dispersion of ARN-509 and HPMCAS is obtainable, in particular is obtained, by melt-extruding a mixture comprising ARN-509 and HPMCAS and optionally subsequently milling said melt-extruded mixture. In one aspect, the solid dispersion of ARN-509 and HPMCAS is obtainable, in particular is obtained, by spray drying a mixture comprising ARN-509 and HPMCAS in a suitable solvent. |
| Inventor(s): | Dennis Martin Hester, Jason Michael Vaughn |
| Assignee: | Aragon Pharmaceuticals Inc |
| Application Number: | US18/660,698 |
| Patent Litigation and PTAB cases: | See patent lawsuits and PTAB cases for patent 12,303,493 |
|
Patent Claim Types: see list of patent claims | Composition; Formulation; Compound; Process; Dosage form; |
| Patent landscape, scope, and claims: |
More… ↓ |
Drugs Protected by US Patent 12,303,493
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Patented / Exclusive Use | Submissiondate |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Janssen Biotech | ERLEADA | apalutamide | TABLET;ORAL | 210951-001 | Feb 14, 2018 | AB | RX | Yes | No | 12,303,493 | ⤷ Start Trial | Y | ⤷ Start Trial | |||
| Janssen Biotech | ERLEADA | apalutamide | TABLET;ORAL | 210951-002 | Feb 17, 2023 | RX | Yes | Yes | 12,303,493 | ⤷ Start Trial | Y | ⤷ Start Trial | ||||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Patented / Exclusive Use | >Submissiondate |
International Family Members for US Patent 12,303,493
| Country | Patent Number | Estimated Expiration | Supplementary Protection Certificate | SPC Country | SPC Expiration |
|---|---|---|---|---|---|
| Argentina | 102926 | ⤷ Start Trial | |||
| Australia | 2015358490 | ⤷ Start Trial | |||
| Australia | 2021201979 | ⤷ Start Trial | |||
| Australia | 2023202710 | ⤷ Start Trial | |||
| Brazil | 112017011788 | ⤷ Start Trial | |||
| >Country | >Patent Number | >Estimated Expiration | >Supplementary Protection Certificate | >SPC Country | >SPC Expiration |
